Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05483257

Enrollment

226

Registered

2022-08-02

Start date

2018-03-14

Completion date

2021-09-13

Last updated

2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer Resectable

Keywords

human leukocyte antigen class I, supertypes, recurrence

Brief summary

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Interventions

DEVICEMultigene panel for next-generation sequencing

HLA-I genotyping based on next-generation sequencing for prognosis evaluation

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

34 Years to 84 Years

Healthy volunteers

Inclusion criteria

* Radically resected pancreatic adenocarcinoma (stage I-III) * Resected tumor tissues and matched blood cells available * Signed informed consent

Exclusion criteria

* Pancreatic cancer except pancreatic adenocarcinoma * Non-radical resection

Design outcomes

Primary

Measure	Time frame	Description
Disease-free survival (DFS)	2 years	Comparison of DFS between patients with specific HLA-I genotypes or not

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026